With a particle size of 553 nm and a zeta potential of -31.87 mV, it stays dispersed and stable, ensuring every dose works effectively
What it does in the MicroInfuser context: dermal hydration (low-MW), volumetric plumping in upper dermis (mid-MW), barrier-protective film in the post-procedure window (high-MW), and CD44 receptor engagement on fibroblasts
Smith et al., 2024)
Unlike most peptides, BPC-157 is remarkably stable in an acidic gastric environment (pH 1-2) for more than 24 hours, making it a candidate for oral administration in research
In experiments employing the MCAO/R model, PCs significantly reduced neurological impairment scores at various intervals1, 24, 72 h, and 7 days post-MCAO
Who should avoid Epithalon Absolute contraindications: Pregnancy or breastfeeding (no safety data) Active cancer diagnosis (telomerase concerns) Children and adolescents (still developing) Severe kidney or liver disease (clearance issues) Relative contraindications (use caution): Autoimmune conditions (immune stimulation could worsen) History of cancer (even if in remission - discuss with oncologist) Severe sleep disorders (pineal effects unpredictable) Taking immunosuppressants (opposing effects) Severe mental health conditions (monitor carefully) When to consult physician: Any chronic medical conditions Taking prescription medications History of adverse peptide reactions Uncertain about appropriateness Want medical monitoring during treatment Age considerations: Under 30: Questionable benefit (telomeres still long, aging minimal ) 30-50: Preventive use reasonable, moderate benefits 50+: Best candidates, age-related decline more pronounced 70+: Still beneficial but more medical monitoring advised Find peptide therapy clinics for supervised treatment at SeekPeptides
